×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IBIO – ibio, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IBIO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/9
07:00 am
ibio
iBio Announces $26 Million Private Placement
Medium
Report
iBio Announces $26 Million Private Placement
12/19
05:58 am
ibio
iBio (NASDAQ:IBIO) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Medium
Report
iBio (NASDAQ:IBIO) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
12/16
04:37 pm
ibio
iBio (NASDAQ:IBIO) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
iBio (NASDAQ:IBIO) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/24
04:15 pm
ibio
iBio to Participate in the 8th Annual Evercore Healthcare Conference
Medium
Report
iBio to Participate in the 8th Annual Evercore Healthcare Conference
11/16
01:09 am
ibio
iBio (NASDAQ:IBIO) was upgraded by analysts at Wall Street Zen from
Medium
Report
iBio (NASDAQ:IBIO) was upgraded by analysts at Wall Street Zen from
11/12
04:27 pm
ibio
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/12
04:01 pm
ibio
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
Medium
Report
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/30
06:16 am
ibio
Form 4 iBio, Inc. For: Jan 28 Filed by: Banjak Marc
Low
Report
Form 4 iBio, Inc. For: Jan 28 Filed by: Banjak Marc
1/30
06:16 am
ibio
Form 4 iBio, Inc. For: Jan 28 Filed by: Duran Felipe
Low
Report
Form 4 iBio, Inc. For: Jan 28 Filed by: Duran Felipe
1/30
06:15 am
ibio
Form 4 iBio, Inc. For: Jan 28 Filed by: Brenner Martin
Low
Report
Form 4 iBio, Inc. For: Jan 28 Filed by: Brenner Martin
1/29
09:30 pm
ibio
Form SCHEDULE 13G/A iBio, Inc. Filed by: Affinity Asset Advisors, LLC
Low
Report
Form SCHEDULE 13G/A iBio, Inc. Filed by: Affinity Asset Advisors, LLC
1/22
05:03 pm
ibio
Form SCHEDULE 13G iBio, Inc. Filed by: INTEGRATED CORE STRATEGIES (US) LLC
Medium
Report
Form SCHEDULE 13G iBio, Inc. Filed by: INTEGRATED CORE STRATEGIES (US) LLC
1/12
05:30 pm
ibio
Form 8-K iBio, Inc. For: Jan 08
Medium
Report
Form 8-K iBio, Inc. For: Jan 08
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/2
iBio to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference
41.4%
2/3 iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine 39.6%
2/28 Form S-3 iBio, Inc. 28.9%
8/19 iBio Inks 3D Bioprinting Agreement 28.6%
3/18 iBio Announces Development of Proprietary COVID-19 Vaccine Candidates 12.2%
8/26 iBio and CC-Pharming Expand Business Collaboration in China 10.5%
3/12 iBio Announces Leadership Succession, Appoints Thomas F. Isett Co-Chairman & CEO 9.6%
2/25 Form 8-K/A iBio, Inc. For: Feb 20 9.5%
3/23 Form 4 iBio, Inc. For: Mar 17 Filed by: Isett Thomas Francis 3rd 6.9%
4/27 iBio Estimates ~500 Million Dose Capacity for COVID-19 Vaccine from its FastPharming Facility™ 6.7%
2/3 iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine 39.6%
2/28 Form S-3 iBio, Inc. 28.9%
8/19 iBio Inks 3D Bioprinting Agreement 28.6%
3/18 iBio Announces Development of Proprietary COVID-19 Vaccine Candidates 12.2%
8/26 iBio and CC-Pharming Expand Business Collaboration in China 10.5%
3/12 iBio Announces Leadership Succession, Appoints Thomas F. Isett Co-Chairman & CEO 9.6%
2/25 Form 8-K/A iBio, Inc. For: Feb 20 9.5%
3/23 Form 4 iBio, Inc. For: Mar 17 Filed by: Isett Thomas Francis 3rd 6.9%
4/27 iBio Estimates ~500 Million Dose Capacity for COVID-19 Vaccine from its FastPharming Facility™ 6.7%
TOP News Decliners
10/25
iBio, Inc. Prices $5,000,000 Public Offering
-51.2%
3/2 Form DEFA14A iBio, Inc. -30.9%
10/24 Form S-1/A iBio, Inc. -27.4%
3/2 Thinking about buying stock in Aurora Cannabis, Chesapeake Energy Corp, FuelCell Energy, iBio, or Pinterest? -23.8%
3/9 Form 8-K iBio, Inc. For: Mar 05 -22.3%
8/20 Thinking about buying stock in Apache, CNH Industrial, Home Depot, Ibio, or Vivus? -20.4%
1/13 Form PRE 14A iBio, Inc. For: Feb 10 -18.2%
10/28 Form 8-K iBio, Inc. For: Oct 25 -16.5%
3/18 Form 8-K iBio, Inc. For: Mar 18 -15.4%
4/9 iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute -15.0%
3/2 Form DEFA14A iBio, Inc. -30.9%
10/24 Form S-1/A iBio, Inc. -27.4%
3/2 Thinking about buying stock in Aurora Cannabis, Chesapeake Energy Corp, FuelCell Energy, iBio, or Pinterest? -23.8%
3/9 Form 8-K iBio, Inc. For: Mar 05 -22.3%
8/20 Thinking about buying stock in Apache, CNH Industrial, Home Depot, Ibio, or Vivus? -20.4%
1/13 Form PRE 14A iBio, Inc. For: Feb 10 -18.2%
10/28 Form 8-K iBio, Inc. For: Oct 25 -16.5%
3/18 Form 8-K iBio, Inc. For: Mar 18 -15.4%
4/9 iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute -15.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: